Does cancer clinical trial enrollment for sexual and gender minority people differ from heterosexual, cisgender people?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: United States NLM ID: 101242342 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-2030 (Electronic) Linking ISSN: 15517144 NLM ISO Abbreviation: Contemp Clin Trials Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, N.Y. : Elsevier, c2005-
    • Subject Terms:
      Sexual and Gender Minorities*/statistics & numerical data ; Heterosexuality*/statistics & numerical data ; Clinical Trials as Topic* ; Neoplasms*/therapy; Humans ; Male ; Female ; Middle Aged ; Adult ; Behavioral Risk Factor Surveillance System ; Patient Selection ; Aged ; Young Adult ; United States
    • Abstract:
      Background: Sexual and gender minority (SGM) people experience cancer disparities compared to heterosexual and cisgender (non-SGM) people and likely have barriers to cancer clinical trial enrollment. Data are sparse, however, regarding cancer clinical trial enrollment for SGM versus non-SGM people.
      Methods: Using data from the 2020 Behavioral Risk Factor Surveillance Survey (BRFSS), we applied a logistic regression to assess associations between SGM status and clinical trial enrollment for 346 SGM and 9441 non-SGM people diagnosed with cancer. The model was adjusted for age at diagnosis, race/ethnicity, partnership status, education, employment, and sex assigned at birth.
      Results: SGM individuals had 94 % greater odds than non-SGM individuals to report participation in a clinical trial (aOR 1.94; 95 % CI 1.02-3.68) after adjusting for other factors.
      Conclusions: Data from the BRFSS suggest that SGM people with cancer have higher odds of clinical trial enrollment compared to non-SGM people with cancer. Future work is needed to prospectively track oncology treatment, including clinical trial participation, and outcomes of SGM people versus non-SGM people with cancer. Other studies will be needed to develop and implement systematic, consistent, and non-stigmatizing sexual orientation and gender identity data collection methods.
      Competing Interests: Declaration of competing interest Dr. Juno Obedin-Maliver has consulted for Sage Therapeutics (2017), Ibis Reproductive Health (2017-2018, 2020-present), Hims, Incorporated (2019-present), Folx, Incorporated (2019-present), and Upstream Incorporate (2024). These organizations have had no influence on the research, analysis, or intepretation of findings in this manuscript.
      (Copyright © 2024 Elsevier Inc. All rights reserved.)
    • Grant Information:
      T32 HS000011 United States HS AHRQ HHS
    • Contributed Indexing:
      Keywords: Clinical trial; Oncology; Sexual and gender minorities
    • Publication Date:
      Date Created: 20240920 Date Completed: 20241102 Latest Revision: 20241102
    • Publication Date:
      20241103
    • Accession Number:
      10.1016/j.cct.2024.107695
    • Accession Number:
      39303766